Baran David A
Newark Beth Israel Medical Center, Newark, NJ 07112, USA.
Heart Fail Clin. 2007 Jan;3(1):31-41. doi: 10.1016/j.hfc.2007.02.009.
Induction therapy has continued to be a subject of controversy in heart transplantation for more than 20 years. It is an example of a therapy that is logical, and ought to be better than "doing without." However, a careful review of the evidence suggests otherwise. Except for patients where the benefits clearly outweigh the short and long-term risks, the use of induction therapy should be avoided. In immunosuppression, as in life, there is no "free lunch." Clinicians need to be certain they fully understand what they are ordering when asking for induction therapy to be administered to their patients.
20多年来，诱导治疗一直是心脏移植领域争论的焦点。这是一种看似合理的治疗方法，理应比“不进行治疗”更好。然而，对证据的仔细审查却表明并非如此。除了那些受益明显超过短期和长期风险的患者外，应避免使用诱导治疗。在免疫抑制治疗中，就像在生活中一样，没有“免费的午餐”。临床医生在要求对患者进行诱导治疗时，需要确保他们完全清楚自己所开具的治疗方案。
